Skip to main content
Clinical Trials/NCT06030596
NCT06030596
Recruiting
Not Applicable

SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve

China National Center for Cardiovascular Diseases1 site in 1 country210 target enrollmentSeptember 9, 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Coronary Artery Disease
Sponsor
China National Center for Cardiovascular Diseases
Enrollment
210
Locations
1
Primary Endpoint
The diagnostic accuracy of MBF and MFR derived from SPECT
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

Recent evidences have demonstrated improved diagnostic accuracy for detecting coronary artery disease (CAD) when myocardial blood flow (MBF) is quantified in absolute terms using single photon emission tomography (SPECT) compared to conventional myocardial perfusion imaging (MPI). However, there are no uniformly accepted cutoff values of MBF and MFR derived from SPECT for diagnosing hemodynamically significant CAD. Particularly, the diagnostic performance for quantitative SPECT has not been validated using fractional flow reserve (FFR). The aim of this prospective study is to determine optimal cutoff values of absolute MBF and MFR derived from NaI (Tl)-based SPECT and to evaluate the diagnostic efficacy of this quantitative technology utilizing invasive coronary angiography (ICA) in combination with FFR results as the reference standard in patients with suspected or known CAD.

Registry
clinicaltrials.gov
Start Date
September 9, 2022
End Date
December 2023
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
China National Center for Cardiovascular Diseases
Responsible Party
Principal Investigator
Principal Investigator

Wei Fang

MD

China National Center for Cardiovascular Diseases

Eligibility Criteria

Inclusion Criteria

  • Age 18 \~ 79 years old
  • At least one CAD risk factor
  • Intermediate to high pre-test likelihood for CAD
  • Suspected or known CAD, clinically referred for invasive coronary angiography
  • Able and willing to comply with the study procedures
  • Written informed consent

Exclusion Criteria

  • History or risk of severe bradycardia
  • History of myocardial infarction, dilated cardiomyopathy, hypertrophic cardiomyopathy, valve issue or congenital heart disease
  • Wheezing asthma or COPD
  • Known second- or third-degree AV block
  • Known hypersensitivity to dipyridamole or adenosine
  • Known coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI) prior to screening
  • Breastfeeding or pregnancy
  • Claustrophobia or inability to lie still in a supine position
  • Unwillingness or inability to provide informed consent

Outcomes

Primary Outcomes

The diagnostic accuracy of MBF and MFR derived from SPECT

Time Frame: 1 year

The diagnostic sensitivity, specificity, accuracy of MBF and MFR derived from SPECT for the detection of hemodynamically significant coronary artery disease as defined by invasive coronary angiography in combination with fractional flow reserve measurements.

Study Sites (1)

Loading locations...

Similar Trials